These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 19540427)
1. Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Chen M; Li XR; Zhou YX; Yang KW; Chen XW; Deng Q; Liu Y; Ren LJ Peptides; 2009 Jul; 30(7):1288-95. PubMed ID: 19540427 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Morimoto K; Katsumata H; Yabuta T; Iwanaga K; Kakemi M; Tabata Y; Ikada Y Eur J Pharm Sci; 2001 May; 13(2):179-85. PubMed ID: 11297902 [TBL] [Abstract][Full Text] [Related]
3. [The hypocalcemia effect of salmon calcitonin ultra-flexible liposomes after intranasal administration in rats]. Chen M; Deng Q; Li XR; Liu Y Yao Xue Xue Bao; 2007 Jun; 42(6):681-6. PubMed ID: 17702409 [TBL] [Abstract][Full Text] [Related]
4. Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride. du Plessis LH; Lubbe J; Strauss T; Kotzé AF Int J Pharm; 2010 Jan; 385(1-2):181-6. PubMed ID: 19854253 [TBL] [Abstract][Full Text] [Related]
5. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep. Hinchcliffe M; Jabbal-Gill I; Smith A J Pharm Pharmacol; 2005 Jun; 57(6):681-7. PubMed ID: 15969922 [TBL] [Abstract][Full Text] [Related]
6. Oral absorption enhancement of salmon calcitonin by using both N-trimethyl chitosan chloride and oligoarginines-modified liposomes as the carriers. Huang A; Su Z; Li S; Sun M; Xiao Y; Ping Q; Deng Y Drug Deliv; 2014 Aug; 21(5):388-96. PubMed ID: 24188463 [TBL] [Abstract][Full Text] [Related]
7. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats. Lee KC; Park MO; Na DH; Youn YS; Lee SD; Yoo SD; Lee HS; DeLuca PP Calcif Tissue Int; 2003 Dec; 73(6):545-9. PubMed ID: 14508623 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of nasal absorption of calcitonin loaded in liposomes. Law SL; Huang KJ; Chou VH; Cherng JY J Liposome Res; 2001; 11(2-3):165-74. PubMed ID: 19530931 [TBL] [Abstract][Full Text] [Related]
9. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin. Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061 [TBL] [Abstract][Full Text] [Related]
10. Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits. Schipper NG; Romeijn SG; Verhoef J; Merkus FW Calcif Tissue Int; 1994 Jan; 54(1):50-5. PubMed ID: 8118754 [TBL] [Abstract][Full Text] [Related]
12. Characterization of calcitonin-containing liposome formulations for intranasal delivery. Law SL; Shih CL J Microencapsul; 2001; 18(2):211-21. PubMed ID: 11253938 [TBL] [Abstract][Full Text] [Related]
13. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Garcia-Fuentes M; Prego C; Torres D; Alonso MJ Eur J Pharm Sci; 2005 May; 25(1):133-43. PubMed ID: 15854809 [TBL] [Abstract][Full Text] [Related]
14. Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes. Cho W; Kim MS; Jung MS; Park J; Cha KH; Kim JS; Park HJ; Alhalaweh A; Velaga SP; Hwang SJ Int J Pharm; 2015 Jan; 478(1):288-296. PubMed ID: 25445994 [TBL] [Abstract][Full Text] [Related]
15. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. Youn YS; Jung JY; Oh SH; Yoo SD; Lee KC J Control Release; 2006 Sep; 114(3):334-42. PubMed ID: 16884808 [TBL] [Abstract][Full Text] [Related]
16. Methylated beta-cyclodextrins are able to improve the nasal absorption of salmon calcitonin. Schipper NG; Verhoef JC; Romeijn SG; Merkus FW Calcif Tissue Int; 1995 Apr; 56(4):280-2. PubMed ID: 7767838 [TBL] [Abstract][Full Text] [Related]
17. Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. Yamabe K; Kato Y; Onishi H; Machida Y J Control Release; 2003 May; 89(3):429-36. PubMed ID: 12737845 [TBL] [Abstract][Full Text] [Related]
18. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. Youn YS; Kwon MJ; Na DH; Chae SY; Lee S; Lee KC J Control Release; 2008 Jan; 125(1):68-75. PubMed ID: 18023905 [TBL] [Abstract][Full Text] [Related]
19. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. Song KH; Chung SJ; Shim CK J Control Release; 2005 Sep; 106(3):298-308. PubMed ID: 15979756 [TBL] [Abstract][Full Text] [Related]
20. The influence of the enhancer dimyristoylphosphatidylglycerol and formulation factors on the nasal absorption of salmon calcitonin. Dua R; Duncan M; Zia H; Needham TE Drug Deliv; 1998; 5(2):127-34. PubMed ID: 19570004 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]